PRESS RELEASE published on 03/28/2025 at 07:00, 1 year 2 months ago Communiqué de presse : Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO Le Dupixent est le premier biomédicament approuvé au Japon pour traiter la BPCO, avec des résultats positifs provenant d'études de phase III. Paris, New York - 28 mars 2025 Japon BPCO Dupixent Étude De Phase III Biomédicament
PRESS RELEASE published on 03/24/2025 at 19:27, 1 year 2 months ago Sanofi : Déclaration des transactions sur actions propres
PRESS RELEASE published on 03/24/2025 at 19:27, 1 year 2 months ago Sanofi: Disclosure of trading in own shares
BRIEF published on 03/24/2025 at 07:35, 1 year 2 months ago Mise en ligne du document « Q1 2025 Aide mémoire » par Sanofi Résultats Financiers Investisseurs Sanofi Aide Mémoire Q1 2025
BRIEF published on 03/24/2025 at 07:35, 1 year 2 months ago Sanofi launches the “Q1 2025 Aide mémoire” document Financial Results Investors Sanofi Q1 2025 Memory Aid
PRESS RELEASE published on 03/24/2025 at 07:30, 1 year 2 months ago Communiqué de presse : Mise en ligne du document « Q1 2025 Aide mémoire » Annonce de la mise en ligne du document 'Q1 2025 Aide mémoire' par Sanofi sur l'espace Investisseurs du site internet. Résultats du premier trimestre 2025 à venir le 24 avril 2025 Annonce Résultats Trimestriels Sanofi Q1 2025 Document En Ligne
PRESS RELEASE published on 03/24/2025 at 07:30, 1 year 2 months ago Press Release: Availability of the Q1 2025 Aide mémoire Sanofi announced the availability of the Q1 2025 Aide mémoire on its website to assist in financial modeling, including non-comparable items and first quarter reminders Sanofi Financial Modeling Aide Mémoire Q1 2025 Exclusivity Losses
PRESS RELEASE published on 03/10/2025 at 21:09, 1 year 2 months ago Sanofi: Disclosure of trading in own shares
PRESS RELEASE published on 03/10/2025 at 21:09, 1 year 2 months ago Sanofi : Déclaration des transactions sur actions propres
BRIEF published on 03/08/2025 at 19:05, 1 year 2 months ago Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
Published on 06/01/2026 at 09:05, 59 minutes ago Nano One Announces Retirement of Founder and CEO Dan Blondal, President & Chief Strategy Officer Alex Holmes Appointed to CEO Role
Published on 06/01/2026 at 09:05, 59 minutes ago Nano One annonce la retraite du Fondateur et Chef de la direction, Dan Blondal, Le Président et Chef de la stratégie Alex Holmes nommé au poste de PDG
Published on 06/01/2026 at 08:00, 2 hours 4 minutes ago Grande Portage Resources Advances Ongoing Project Studies and Fieldwork to Support New Amalga Gold Project Development
Published on 05/30/2026 at 04:00, 2 days 6 hours ago Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform
Published on 05/30/2026 at 02:40, 2 days 7 hours ago BEACN Announces Financial Results for the First Quarter of 2026 and Update on Loan
Published on 06/01/2026 at 09:46, 17 minutes ago Original-Research: Aroundtown SA (von First Berlin Equity Research GmbH): Kaufen
Published on 06/01/2026 at 09:44, 19 minutes ago MARTIN KRÄMER BECOMES THE NEW CHIEF FINANCIAL OFFICER AT CHEPLAPHARM
Published on 06/01/2026 at 09:35, 28 minutes ago ENGWE Launches Y700ABE E-scooter in Germany for Long-Range Urban Commuting
Published on 06/01/2026 at 08:01, 2 hours 2 minutes ago Saint-Gobain divests HKO, a high-temperature industrial insulation textile business
Published on 06/01/2026 at 06:59, 3 hours 5 minutes ago OPmobility et Yanfeng finalisent le renforcement de leur filiale chinoise YFPO
Published on 06/01/2026 at 06:59, 3 hours 5 minutes ago OPmobility and Yanfeng finalize the strengthening of their Chinese joint venture YFPO
Published on 05/29/2026 at 22:00, 2 days 12 hours ago Information on the Annual Financial Statements 2025
